Expertise in
25
conditions

Dr. Lisa Forman

Hepatology
University Physicians Incorporated
12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 
Offers Telehealth
Expertise in
25
conditions
University Physicians Incorporated
12605 E 16th Ave, Uchealth Anschutz Medical, 
Aurora, CO 

Overview

Lisa Forman is a Hepatologist in Aurora, Colorado. Dr. Forman is highly rated in 25 conditions, according to our data. Her top areas of expertise are Cholangitis, Sclerosing Cholangitis, Primary Biliary Cholangitis, Liver Transplant, and Endoscopy.

Her clinical research consists of co-authoring 30 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hepatology

Licenses

Internal Medicine in CO

Hospital Affiliations

Uchealth Highlands Ranch Hospital
Poudre Valley Hospital
University Of Colorado Hospital Authority
Uchealth Broomfield Hospital
Medical Center Of The Rockies

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Denver Health Medical Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Group Health Cooperative
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Rocky Mountain Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
SelectHealth
  • HMO
  • POS
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Sky Community Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER COMMERCIAL
View 16 Less Insurance Carriers -

Locations

UNIVERSITY PHYSICIANS INCORPORATED
12605 E 16th Ave, Uchealth Anschutz Medical, Aurora, CO 80045

Additional Areas of Focus

Dr. Forman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: February 04, 2026
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Phase: Phase 2
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Enrollment Status: Completed
Publish Date: January 29, 2025
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
A Phase 2, Randomized, Double Blind, Placebo Controlled, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of Seladelpar Administered for 24 Weeks in Adult Patients With Primary Sclerosing Cholangitis (PSC)
Enrollment Status: Terminated
Publish Date: January 16, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: August 02, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 7 Less Clinical Trials

30 Total Publications

Sensory Entrained TMS (seTMS) enhances motor cortex plasticity.
Sensory Entrained TMS (seTMS) enhances motor cortex plasticity.
Journal: bioRxiv : the preprint server for biology
Published: August 08, 2025
Similar Doctors
Expertise in
17
conditions
Dr. Amanda Wieland
Hepatology
Expertise in
17
conditions
Dr. Amanda Wieland
Hepatology

University Of Colorado Hospital Authority

1635 Aurora Ct, 
Aurora, CO 
 (0.2 miles away)
720-848-2245
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Amanda Wieland is a Hepatologist in Aurora, Colorado. Dr. Wieland is highly rated in 17 conditions, according to our data. Her top areas of expertise are Non-Alcoholic Fatty Liver Disease, Visceromegaly, Enlarged Liver, Endoscopy, and Liver Transplant.

Expertise in
18
conditions
Dr. Clark Kulig
Hepatology
Expertise in
18
conditions
Dr. Clark Kulig
Hepatology

Portercare Adventist Health System

6031 E Woodmen Rd, Suite 100, 
Colorado Springs, CO 
 (56.0 miles away)
303-778-5797
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Clark Kulig is a Hepatologist in Colorado Springs, Colorado. Dr. Kulig is highly rated in 18 conditions, according to our data. His top areas of expertise are Liver Failure, Hepatitis, Fibrolamellar Carcinoma, Esophageal Varices, and Endoscopy.

Expertise in
2
conditions
Dr. Aimee E. Truesdale
Gastroenterology | Hepatology
Expertise in
2
conditions
Dr. Aimee E. Truesdale
Gastroenterology | Hepatology

South Denver Gastroenterology, PC

9397 Crown Crest Blvd, Ste 420, 
Parker, CO 
 (14.0 miles away)
303-788-8888
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Aimee Truesdale is a Hepatologist and a Gastroenterologist in Parker, Colorado. Dr. Truesdale is highly rated in 2 conditions, according to our data. Her top areas of expertise are Hepatitis C, Hepatitis, Alcoholic Cirrhosis, Visceromegaly, and Endoscopy. Dr. Truesdale is currently accepting new patients.

Frequently Asked Questions about Dr. Lisa Forman

How do I make an appointment with Dr. Lisa Forman?

You can book an appointment with Dr. Lisa Forman by calling their office at 720-848-0000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Lisa Forman a top-rated expert for Cholangitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Lisa Forman is classified as an Elite expert for Cholangitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Lisa Forman specialize in?

While Dr. Lisa Forman is a Hepatology, they have specific expertise in Cholangitis, Sclerosing Cholangitis, and Primary Biliary Cholangitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hepatology.

Does Dr. Lisa Forman participate in research or clinical trials?

Yes. Dr. Lisa Forman has published 30 articles and abstracts on conditions like Cholangitis. You can view a list of Dr. Lisa Forman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Lisa Forman accept my insurance?

Dr. Lisa Forman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 720-848-0000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Forman's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 11 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile